Pay in 4 interest-free payments of $5.90 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
~0.7mg 1.3mg 2.7mg 3x/week 3 injections/week P/T Ratio: ~1.6 Peak Reduction: 35% 4
The LEAD-1 study provided clinical input and compared glimepiride with two doses of liraglutide (1.2 mg and 1.8 mg) and rosiglitazone (4 mg) in patients with type 2 diabetes mellitus (T2DM) (16)
10.5005/jp-journals-10005-1511 162
Temporal requirements of insulin/IGF-1 signaling for proteotoxicity protection [PMID: 20003171] Laboratory literature summary: Temporal requirements of insulin/IGF-1 signaling for proteotoxicity protection
US$ 20.07
US$ 29.74
US$ 22.75
US$ 25.70
US$ 22.30
US$ 23.52
US$ 22.74
US$ 26.78
US$ 25.37
US$ 24.76
US$ 25.98
